Full-Time
Confirmed live in the last 24 hours
Develops targeted therapies for cancer and allergies
No salary listed
Senior
Cambridge, MA, USA
Blueprint Medicines develops biopharmaceuticals aimed at treating serious medical conditions, focusing on allergy/inflammation and oncology/hematology. Their medicines work by targeting the underlying causes of diseases, utilizing extensive scientific knowledge and drug discovery methods. Unlike many competitors, Blueprint Medicines has a strong track record with two approved drugs and is advancing a diverse pipeline that includes treatments for mast cell diseases and various cancers. The company's goal is to alleviate human suffering by creating effective therapies while fostering a collaborative and inclusive work environment for its employees.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2011
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Commuter Benefits
Mental Health Support
Employee Stock Purchase Plan
Parental Leave
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS - April 24, 2025 - Agendia(R), Inc., announced today that new MammaPrint and BluePrint data and their ability to inform axillary surgery decisions in the neoadjuvant setting will be presented at the 26th American Society of Breast Surgeons Annual Meeting (ASBrS), taking place in Las Vegas, NV, April 30 - May 4, 2025.
Proficio Capital Partners LLC makes new $1.01 million investment in Blueprint Medicines Co. (NASDAQ:BPMC).
Truist Financial Corp makes new investment in Blueprint Medicines Co. (NASDAQ:BPMC).
Blueprint Medicines highlights 'decade of leadership' in Mast Cell research with new AYVAKIT and BLU-808 data at AAAAI/WAO 2025.
-- Updated data show AYVAKIT® (avapritinib) was safe and effective for long-term treatment of ISM, with sustained symptom and quality-of-life benefit and no new safety signals with multiple years of therapy ---- AYVAKIT-treated patients achieved improvements in bone health based on an analysis of bone mineral density scans, underscoring the importance of treating patients early in the ISM disease course ---- BLU-808 healthy volunteer trial results demonstrate wide therapeutic window for modulating mast cell activity, affirming potential as best- and first-in-class oral wild-type KIT inhibitor --CAMBRIDGE, Mass., Feb. 28, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting its ongoing efforts to innovate the treatment of mast cell-driven diseases. The presentations include three-year median follow-up data from the registrational PIONEER trial demonstrating the strong long-term efficacy and safety of AYVAKIT® (avapritinib) in patients with indolent systemic mastocytosis (ISM), and real-world evidence further characterizing the substantial burden of the disease, highlighting the urgency to treat. In addition, the company will report positive data from the Phase 1 healthy volunteer trial evaluating BLU-808, an investigational, highly potent and selective oral inhibitor of wild-type KIT, consistent with top-line data previously announced in January 2025. A total of 14 data presentations, including two oral presentations, will be reported at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress being held February 28-March 3 in San Diego."We are incredibly proud to showcase our mast cell therapy portfolio at AAAAI / WAO, with 14 presentations highlighting more than a decade of leadership and collaboration with the mast cell disease community, including renowned medical institutions pioneering innovative research and multi-disciplinary patient care," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. "In ISM, new data have reinforced that AYVAKIT was very well-tolerated after multiple years of treatment, with a low discontinuation rate and safety results that have remained consistent with the safety profile from the placebo-controlled study as summarized in the FDA-approval label